Biogen and Samsung Bioepis Agree to Settlement with AbbVie Allowing Commercialization of IMRALDI™ (Adalimumab Biosimilar) in Europe
Biogen Inc. (Nasdaq: BIIB) and its partner Samsung Bioepis announced today an agreement with AbbVie (NYSE: ABBV) for the commercialization of IMRALDI, a biosimilar referencing HUMIRA® (adalimumab). Under terms of the agreement, AbbVie will grant patent licenses for the use and sale of IMRALDI in Europe, on a country-by-country basis, and Biogen and Samsung Bioepis will make royalty payments to AbbVie. The companies have agreed to dismiss all pending patent litigation.
Biogen expects to launch IMRALDI in Europe on October 16, 2018, which will complement its existing portfolio of anti-TNF therapies, BENEPALI™ (etanercept) and FLIXABI™ (infliximab).
“Biogen is a leader in the emerging field of biosimilars through Samsung Bioepis, our joint venture with Samsung BioLogics,” said Ian Henshaw, Global Head of Biosimilars at Biogen. “Biogen already markets two biosimilars in Europe and the planned introduction of IMRALDI on October 16 could potentially expand patient choice by offering physicians more options to meet the needs of patients while delivering significant savings to healthcare systems.”
The precise terms of the agreement with AbbVie are confidential.
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases. Founded in 1978 as one of the world’s first global biotechnology companies by Charles Weissmann, Heinz Schaller, Kenneth Murray, and Nobel Prize winners Walter Gilbert and Phillip Sharp, today Biogen has the leading portfolio of medicines to treat multiple sclerosis; has introduced the first and only approved treatment for spinal muscular atrophy; and is focused on advancing neuroscience research programs in Alzheimer’s disease and dementia, multiple sclerosis and neuroimmunology, movement disorders, neuromuscular disorders, pain, ophthalmology, neuropsychiatry, and acute neurology. Biogen also manufactures and commercializes biosimilars of advanced biologics. We routinely post information that may be important to investors on our website at www.biogen.com.
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements relating to the potential benefits, safety, and efficacy of IMRALDI, planning and timing for commercial launch, and the potential of Biogen’s commercial business and pipeline programs, including IMRALDI, BENEPALI, and FLIXABI. These forward-looking statements may be accompanied by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “except,” “forecast,” “intend,” “may,” “plan,” “potential,” “possible,” “will,” and other words and terms of similar meaning. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. You should not place undue reliance on these statements or the scientific data presented.
These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements, including uncertainty of success in commercialization of IMRALDI, which may be impacted by, among other things, the level of preparedness of healthcare providers to treat patients, difficulties in obtaining or changes in the availability of reimbursement for IMRALDI, the effectiveness of sales and marketing efforts, problems with the manufacturing process for IMRALDI, the occurrence of adverse safety events, failure to obtain regulatory approvals in other jurisdictions, failure to protect intellectual property and other proprietary rights, product liability claims, and third party collaboration risks. The foregoing sets forth many, but not all, of the factors that could cause actual results to differ from Biogen’s expectations in any forward-looking statement. Investors should consider this cautionary statement, as well as the risk factors identified in Biogen’s most recent annual or quarterly report and in other reports Biogen has filed with the Securities and Exchange Commission. These statements are based on Biogen’s current beliefs and expectations and speak only as of the date of this press release. Biogen does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future developments, or otherwise.
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Invengo Releases Latest Version of Its ACUITY Digital Platform for Linen Inventory Management20.9.2018 08:00 | Pressemelding
Invengo today announced hot new improvements to its ACUITY digital platform, underscoring its commitment to help laundry groups, hotels and healthcare facilities take full control over their linen inventories, anywhere and at any time. This new milestone release is a significant leap forward from its previous version, taking linen professionals one step further with 100% automatic real-time linen stock visibility, enabling stock levels optimization and availability through cloud-based reporting, dashboards and data analysis. This latest version of ACUITY provides a superior full cloud-based, software-as-a-service (SaaS) offering for companies seeking a plug-and-play solution, significantly reducing total cost of ownership, technical complexity, and setup time, while providing users with instant access to their linen management platform through a web browser on any device. This eliminates the hassle of hosting and maintaining their own server and dealing with software updates while enjo
Alibaba Announces Smart Mobility Initiatives with Partners20.9.2018 07:17 | Pressemelding
Alibaba Group Holding Limited (NYSE: BABA) announced today a series of smart mobility initiatives in partnership with auto brands and technology service providers. The announcement was made during The Cloud Computing Conference, the company’s largest technology showcase, held over four days in Hangzhou, Alibaba’s home base. Partnering with Bosch on Automated Valet Parking Alibaba Cloud, the cloud-computing arm of Alibaba Group, and Bosch, a leading global supplier of technology services, announced plans to introduce Automated Valet Parking (AVP) solutions in China. Both parties will work together to enable the infrastructure-based, driverless parking solution. The technology is powered by software in a cloud and it will offer a fully automated valet parking service in the near future. As part of the cooperation, Bosch will provide its AVP technology, its experience in systems engineering and its IoT competencies. Alibaba Cloud, meanwhile, will share its technologies and its experience
Egon Zehnder and Mobius Executive Leadership Formalize Exclusive Strategic Partnership20.9.2018 06:01 | Pressemelding
Egon Zehnder, the world’s leadership advisory firm, has entered into a formal partnership with Mobius Executive Leadership, the US and Europe-based premier leadership development firm. The partnership combines the firms’ proprietary methods for accelerating the personal and professional development of senior executives and for stimulating an organization’s ability to transform. “Readiness to lead at the top levels in business and society today requires leaders develop a willingness to understand who they are and who they can become so that they can unlock their full potential – and help their organizations unleash their potential as well,” stated Jill Ader, Egon Zehnder’s Chair-Elect and Co-developer of the Executive Breakthrough Program. “Together with Mobius, we have found success in doing that.” Already collaborating for more than four years, the two firms’ new partnership formally combines Egon Zehnder’s deep leadership advisory experience to the world’s most influential leaders an
Twispay Teams up with Blue Air to Expand Digital Payments20.9.2018 06:00 | Pressemelding
Blue Air, the largest Romanian airline by scheduled passengers flown, and Twispay, Swiss-owned European payment processor and FinTech pioneer, today announced the availability of a payment integration partnership that allows a global clientele to complete online payments through Twispay’s payment services. The airline industry is massively time pressured. Airline companies have learned to adapt business and pricing models according to a wide range of wildly fluctuating variables, from sudden shifts in demand and operational costs to erratic weather patterns. Therefore, the reliability and flexibility of a payment processing integration are paramount. The ability to accept online payments quickly, safely, and with ease is crucial to any 21st - century venture, let alone an airline company. “It was essential for us to establish a partnership with a processing services player who understands and can handle a high volume of transactions and air-travel operational particularities. Additiona
Alibaba A.I. Labs Launches Hospitality Robot20.9.2018 04:00 | Pressemelding
The robotics industry is revolutionizing the world, and Alibaba A.I. Labs is raising the stakes in this cutting-edge industry with the announcement of launching service robots for the hospitality sector starting in October. The news was made at The Computing Conference 2018, which is scheduled for four days till September 22 in Hangzhou, China, the site of Alibaba’s headquarters. Alibaba A.I. Labs is the department leading consumer AI product development at Alibaba. Hotels have until now depended entirely on human labor. But the labs' service robot — from delivering meals to taking laundry to guests — demonstrates what guests can expect at hotels in the future. Guests talk to the robot via voice command, touch and hand gesture, and its responses are driven by AliGenie, the software that powers Alibaba A.I. Labs’ smart speaker, Tmall Genie. “We are excited by this tremendous development that is helping us bridge the gap between guest needs and the response time that they expect. Alibaba
Celltrion Signs 'Incubation' Agreement with Emory University for Development of New Drugs for Atherosclerosis20.9.2018 02:03 | Pressemelding
Celltrion, Inc. (KRX:068270) signed an ‘Incubation’ agreement with Emory University in Atlanta to support the research and development of new drug candidates for atherosclerosis. ‘Incubation’ agreement is one of the open innovation measures by which a company provides its internal resources and capabilities, such as research space and facility, manpower and business operation consulting, to an external research institute or startup so as to support the research and ensure autonomy of the research aimed at developing new drugs or next-generation technology on the condition that the company can preferentially discuss commercialization of the research output. Under the agreement, Celltrion will share Celltrion’s accumulated biologics development expertise with Emory University School of Medicine and the Wallace H. Coulter Department of Biomedical Engineering at Emory University and Georgia Institute of Technology, and provide research costs and manufacturing materials of new drug candidat